||Innovation Pharmaceuticals Cites Recent Academic Literature Showing Host Defense Proteins at Cutting-Edge of Medicine for Multiple Diseases
||Innovation Pharmaceuticals Engages Locust Walk, A Global Life Sciences Transaction Firm
||Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis
||Innovation Pharmaceuticals Signs Agreement for Advanced Oral Tablet Technology in Treating Inflammatory Bowel Disease
||Innovation Pharmaceuticals to Attend 2019 BIO International Convention, June 3-6
||Innovation Pharmaceuticals Announces Non-Binding Term Sheet Signed with Global Pharmaceutical Company to Develop and Commercialize Brilacidin for the Treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis
||Innovation Pharmaceuticals Receives FDA End-of-Phase 2 Meeting Minutes
||Innovation Pharmaceuticals - "JAMA" Article Reinforces Need for Novel Oral Mucositis Treatments in Supportive Cancer Care; Company progresses through first stage of review by European Medicines Agency (EMA) regarding Scientific Advice for planned Phase...